Internal Quality Assurance Program for ERBB2 (HER2) Testing Improves the Selection of Breast Cancer Patients for Treatment with Trastuzumab

Table 1

Results of HER2 protein status as determined by IHC and gene status as determined by FISH in breast cancer patients from the control series.

		FISH
Control series		Not amplified		Equivocal		Amplified		Total
IHC	0	471	97%	7	1%	7	1%	485	67%
	1+	51	85%	1	2%	8	13%	60	8%
	2+	33	65%	5	10%	13	25%	51	7%
	3+	3	2%	0	0%	125	98%	128	18%
	total	558	77%	13	2%	153	21%	724	100%